You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Electronic Image Trial Management System

    SBC: VIRTUALSCOPICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Delays in FDA drug approval are measured in lost lives (estimated to be hundreds of thousands over the last few decades) and increased costs to U.S. citizens for drugs that are eventually approved. One factor contributing to the delay in drug approvals is the widespread use of time-consuming and error-prone manual methods to deliver medical images (i.e. CT, MR, ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Cardiac Regenerative Therapy with Cyclin A2

    SBC: VentriNova, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The morbidity and mortality due to cardiovascular disease is attributed to the lack of significant replicative potential of adult mammalian cardiomyocytes. Thus myocyte loss in response to ischemic injury typically results in scar formation and a decline of cardiac function that is usually irreversible. The cessation of myocyte proliferation is associated with ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  3. Vascular Targeting for Imaging and Treatment of Benign Prostatic Hyperplasia

    SBC: ANDROBIOSYS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Benign Prostatic Hyperplasia/Hypertrophy is a major health problem in the United States, with one-in-three men having urologic problems. Currently available treatment modalities include alpha-blockers that do not affect the underlying pathologic process, and 5-alpha-reductase inhibitors that have significant systemic side-effects. We have discovered that human ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Primary Xenografts of Human Tissue as Surrogates of Cancer In Situ

    SBC: ANDROBIOSYS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): AndroBioSys, Inc. is dedicated to the development of human tissue-based in vivo tools capable of selecting better targeted agents for clinical trials by improved preclinical testing. AndroBioSys has developed the technology for reproducible implantation of primary xenografts of benign and malignant human prostate and kidney tissue. Xenografts have been establis ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  5. Novel therapeutic for Alcoholic Liver Disease

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Alcoholic Liver Disease (ALD) is a progressive liver disease that in advanced stages can result in cirrhosis and liver failure. ALD can be divided in various stages of development: (1) mild alcoholic liver injury, (2) steatosis, (3) alcoholic hepatitis, (4) alcoholic liver fibrosis and (5) cirrhosis. Liver fibrosis is a form of scar formation that is found in a ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  6. Small Molecule Therapeutics for Renal Disease

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetic and non-diabetic nephropathies and the Metabolic Syndrome are associated with chronic kidney disease (CKD) - a program comprising proteinuria, accumulation of profibrotic collagen in the renal interstitium and relentless decline in renal function. CKD remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal d ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  7. Phase I Study of BB3 in Dialysis Patients

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Kidney transplantation is the most effective therapeutic modality for end-stage renal disease; it offers a better quality of life and a longer survival. Despite improvements in surgical and organ preservation techniques over the last decade, renal dysfunction and/or failure remains a significant problem following transplantation. Ischemia-reperfusion injury ass ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Therapeutic for Duchenne Muscular Dystrophy (DMD)

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): A significant body of literature indicates that Hepatocyte Growth Factor (HGF) via potent and direct anti-fibrotic activity protects many organs from the fibrosis-driven pathology. In addition, HGF has been shown to also promote muscle progenitor cells to proliferate to promote the regenerative capacity of the muscle in response to injury or significant work ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Neuroprotective/Restorative Therapy for Ischemic Stroke

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Ischemic Stroke continues to be a major cause of morbidity and mortality in the United States. Currently approved thrombolytic therapy suffers for a narrow therapeutic window and clearly other therapeutic strategies are needed, such as neuroprotective or restorative agents. Unfortunately the quest for a therapeutic remains beset by a history of failed clinical ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic use of small-molecule HGF-mimetic for emphysema

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Emphysema is a major cause of death and disability and afflicts approximately 2 million people. The disease cost more than 2.5 billion in annual health care expenses and causes or contributes to the death of 100,000 people each year in the United States alone. The disease is characterized by destruction of the alveolar wall, permanent enlargement of the airspa ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government